Global Leading Market Research Publisher QYResearch announces the release of its latest report “Peripherally Inserted Central Catheter (PICC Line) – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Peripherally Inserted Central Catheter (PICC Line) market, including market size, share, demand, industry development status, and forecasts for the next few years.
For healthcare providers managing patients requiring extended intravenous therapy—including long-term antibiotics, chemotherapy, total parenteral nutrition (TPN), or frequent blood draws—securing reliable and durable venous access remains a critical challenge. Traditional peripheral intravenous (PIV) lines fail within 3-7 days due to phlebitis, infiltration, or occlusion, while centrally inserted central catheters (CICCs, such as subclavian or jugular lines) carry higher risks of pneumothorax, hemothorax, and insertion-site bleeding. The peripherally inserted central catheter (PICC line) addresses these pain points by offering a long, flexible tube inserted into a peripheral vein (typically the basilic or brachial vein in the upper arm), then advanced through the venous system until its tip is positioned in the superior vena cava (SVC) near the heart. This device provides reliable long-term intravenous access for weeks to months—less invasive than CICCs, more durable than PIV lines—and can be used for administering medications, fluids, nutrition, and blood draws. The global market for peripherally inserted central catheter (PICC line) was estimated to be worth US597millionin2025andisprojectedtoreachUS597millionin2025andisprojectedtoreachUS 821 million, growing at a CAGR of 4.7% from 2026 to 2032. This report delivers a data-driven analysis of market size, market share concentration across leading manufacturers (BD, Teleflex, B. Braun, AngioDynamics, Cardinal Health), product segmentation (valve-type vs. open-end catheters), and end-user application across adult and pediatric populations.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/5514155/peripherally-inserted-central-catheter–picc-line
1. Market Size & Share Outlook: Steady Growth Driven by Outpatient and Home Care Expansion
The global market for PICC lines is experiencing steady growth, driven by expanding indications for long-term IV therapy, shift toward outpatient and home-based infusion care, and increasing adoption of antimicrobial and antithrombogenic catheter coatings. The market was valued at US597millionin2025andisprojectedtoreachUS597millionin2025andisprojectedtoreachUS 821 million by 2032, representing a CAGR of 4.7%—faster than many mature hospital device segments due to favorable demographic and healthcare delivery trends.
Recent market intelligence (Q1 2026): Preliminary supply-side data indicates that market share concentration among the top four manufacturers—BD (Becton, Dickinson and Company), Teleflex, B. Braun, and AngioDynamics—remains significant at approximately 55-60% of the global market. BD (BD PowerPICC, BD Maximal Barrier Trays) and Teleflex (Arrow PICC line) lead the premium segment with valve-based, antimicrobial-coated catheters (US60−120perdevice).Chinesemanufacturers(ZhengzhouDIALLMedicalTechnology,ShandongAndeHealthcareApparatus,FoshanSpecialMedical)havegained∗∗marketshare∗∗inAsia−Pacificandcost−sensitiveexportmarketswithopen−endPICCspricedatUS60−120perdevice).Chinesemanufacturers(ZhengzhouDIALLMedicalTechnology,ShandongAndeHealthcareApparatus,FoshanSpecialMedical)havegained∗∗marketshare∗∗inAsia−Pacificandcost−sensitiveexportmarketswithopen−endPICCspricedatUS 10-25 per device.
Regional growth dynamics: North America remains the largest market (approximately 40-45% of global value), driven by advanced healthcare infrastructure, widespread adoption of PICC teams and vascular access specialists, and supportive reimbursement (CMS OPPS APC 5307, payment US$ 350-500 for PICC insertion including imaging guidance). Europe follows (25-30% market share), with growing emphasis on outpatient and home care (UK, Germany, France developing community infusion services). Asia-Pacific is the fastest-growing region (15-20% CAGR), driven by expanding healthcare investments, large chronic disease populations (cancer, diabetes, renal disease), and rising demand for minimally invasive procedures. Latin America and Middle East & Africa exhibit growing interest in PICC adoption as healthcare standards improve (5-10% of global market).
2. Technology Deep Dive: Valve-type vs. Open-end Catheters
A peripherally inserted central catheter (PICC) is a long, flexible tube inserted into a peripheral vein—typically in the upper arm—and then advanced through the venous system until its tip is positioned in a large central vein, usually near the heart (in the superior vena cava). This type of catheter is used to provide long-term intravenous (IV) access for administering medications, fluids, nutrition, or for drawing blood, especially in patients requiring extended treatment. It offers a less invasive alternative compared to other central venous catheters and can remain in place for weeks to months, provided that it is properly maintained and monitored for potential complications such as infection or thrombosis.
Market segmentation by catheter design:
- Valve-type PICC (dominant premium segment, ~55-60% of market share by value, 40-45% by volume) – Features a pressure-activated safety valve at the catheter tip or in the hub that prevents backflow of blood and air entry when the catheter is not in use (closed-system design). Valves open during infusion (positive pressure) or aspiration (negative pressure). Advantages: reduced risk of air embolism, elimination of need for routine heparin flushing (saline only for maintenance, every 7 days vs. daily for open-end), lower infection rates (CLABSI reduction by 30-40% in published studies). Disadvantages: higher cost (US$ 20-40 premium over open-end), smaller internal lumen diameter (valve mechanism reduces cross-sectional area by 10-15%), potential for valve malfunction (1-3% of long-term catheters). Leading brands: BD PowerPICC (ProValve technology), Teleflex Arrow (Groshong valve, silicone or polyurethane), AngioDynamics (BioFlo valve). Primarily used in adult patients requiring long-term access (oncology, TPN, home IV antibiotics).
- Open-end PICC (traditional segment, ~40-45% of market share by value, 55-60% by volume) – Simple, non-valved catheter with open lumen requiring clamping when not in use to prevent air entry and blood backflow. Requires heparin flushing (10 units/mL, typically daily or after each use) to maintain patency. Advantages: lower cost (US$ 10-25 per device, preferred in emerging markets and pediatric populations), larger internal lumen diameter for same French size (no valve mechanism), simpler construction (fewer failure modes). Disadvantages: higher thrombotic risk (reported occlusion rates 5-15% vs. 2-5% for valve-type), requires heparin (contraindicated in heparin-induced thrombocytopenia/HIT patients), more frequent maintenance (daily flushing vs. weekly). Leading brands: Cardinal Health (Kendall PICC), B. Braun (Certofix PICC), Vygon (LeaderCath), Spectrum Vascular (Spectra PICC). Dominant in pediatric applications (valve-type PICCs often too large or stiff for small veins) and cost-sensitive markets (China, India, Latin America).
Industry insight (patient population segmentation): The PICC line market exhibits clear product selection based on patient age, underlying condition, and expected dwell time. Adult oncology patients (chemotherapy, 3-6 months dwell time) are the largest segment (50-60% of PICC placements), favoring valve-type PICCs for infection reduction (neutropenic patients at high CLABSI risk) and convenience (weekly saline flushing reduces home care visits). Adult TPN and long-term antibiotic patients (6-12 months dwell time) also prefer valve-type. Pediatric patients (neonates, infants, children) require smaller French sizes (1.9-4 Fr vs. 4-6 Fr for adults) and flexible materials (silicone vs. polyurethane), with open-end designs dominating due to availability of small-bore, kink-resistant catheters (BD Pediatric PICC, Vygon Piccolo, Medcomp Pedia-PICC). Emerging markets (China, India, Brazil, Southeast Asia) are primarily open-end PICC users due to cost sensitivity (US10−25vs.US10−25vs.US 60-120), though valve-type penetration is increasing in private hospitals and cancer centers.
3. Market Drivers: Outpatient/Home Infusion, Chronic Disease Burden, and CLABSI Reduction Initiatives
Three factors are shaping the PICC line market:
First, shift toward outpatient and home-based infusion care. Healthcare systems globally are reducing hospital length of stay and shifting long-term intravenous therapy to outpatient infusion centers, skilled nursing facilities, or home care. PICC lines are ideal for this transition: patients discharged with PICC in place can receive home nursing visits or self-administer medications (with training). The U.S. home infusion market (antibiotics, TPN, inotropes, immunoglobulin) grew at 8-10% CAGR 2018-2025, driving PICC placement volume (estimated 40-50% of PICC placements now for home therapy vs. 25-30% in 2015). Europe (UK National Health Service, Germany, France) and Australia have similarly expanded community infusion services post-COVID.
Second, rising prevalence of chronic diseases requiring long-term IV access. Oncology: 1.9 million new cancer diagnoses annually in US (2025), with 60-70% receiving IV chemotherapy (4-6 months, cycle-dependent), many through PICC lines. End-stage renal disease (ESRD): 800,000 US patients on hemodialysis (though AV fistula preferred, PICC used as bridge); 500,000 patients receiving IV iron or erythropoiesis-stimulating agents. Chronic infections: osteomyelitis (20-30 per 100,000, requiring 4-6 weeks IV antibiotics), endocarditis, cystic fibrosis exacerbations. Total parenteral nutrition (TPN): short bowel syndrome, Crohn’s disease, intestinal failure (estimated 40,000-50,000 US patients requiring long-term TPN via PICC or tunneled line). The aging population (US 70+ million adults ≥65 by 2030) will further increase chronic disease burden and PICC demand.
Third, CLABSI (central line-associated bloodstream infection) reduction initiatives. PICC lines carry lower CLABSI risk than non-tunneled CICCs (subclavian, jugular, femoral) due to peripheral insertion site (less skin flora, no central vein direct contamination) and shorter subcutaneous tract. For high-risk patients (neutropenia, burns, ICU), antimicrobial-coated PICCs (chlorhexidine, rifampin-minocycline, silver) reduce CLABSI by 40-60% compared to standard catheters. CMS non-payment for hospital-acquired CLABSI (since 2008) and value-based purchasing incentives have driven adoption of coated catheters (20-30% premium over standard, but cost-effective if preventing 1 CLABSI at US$ 45,000-80,000 per episode). Leading brands: BD PowerPICC with Chloragard (chlorhexidine), AngioDynamics BioFlo (silver/carbon coating), Teleflex Arrow with antimicrobial surface.
Typical user case (Q4 2025): A 62-year-old female with stage III colon cancer requires 6 months of FOLFOX chemotherapy (every 2 weeks, 6 cycles). Hospital vascular access team places a valve-type PICC line (BD PowerPICC 5 Fr dual-lumen, chlorhexidine-coated) in the right basilic vein under ultrasound guidance and tip confirmation via ECG (intracavitary). Post-insertion chest X-ray confirms tip in lower SVC. Patient receives her first chemotherapy cycle within 24 hours of insertion. She is discharged with home care orders: weekly saline flush (10 mL, no heparin), weekly dressing change (chlorhexidine disk + transparent dressing), and monitoring for signs of infection (fever, erythema, drainage). Home health nurse visits weekly; patient completes all 6 cycles without complications. PICC removed on day 175 (5.8 months dwell time). Cost analysis: PICC catheter (US85)+insertionkit/ultrasound/US85)+insertionkit/ultrasound/US 120 facility fee) = US205.ComparedtoperipheralIVsiteinsertionevery2days(12PIVattempts,5daysaveragedwelltime,US205.ComparedtoperipheralIVsiteinsertionevery2days(12PIVattempts,5daysaveragedwelltime,US 20 per PIV insertion + nursing time), PICC saves US$ 35-50 per cycle in supply costs and eliminates 24-30 PIV attempts. Patient satisfaction: high (avoided repeated needle sticks, able to shower with dressing cover, minimal arm movement restriction). The hospital’s CLABSI rate for oncology PICCs: 0.8 per 1,000 line-days (vs. 2.5 per 1,000 line-days for non-coated catheters nationally).
Policy and regulatory update (2025-2026): The U.S. Food and Drug Administration (FDA) issued updated guidance (October 2025) for “Premarket Notification (510(k)) Submissions for Peripherally Inserted Central Catheters,” requiring biocompatibility testing per ISO 10993 series, bench testing for catheter kink resistance (radius of curvature testing, 10 cycles without flow reduction >20%), and simulated use testing in anatomical models (vascular access trainer with venous system). The Centers for Medicare & Medicaid Services (CMS) updated OPPS (Outpatient Prospective Payment System) for 2026: PICC insertion with imaging guidance (APC 5307) payment increased 3.2% (US482.50fromUS482.50fromUS 467.80), reflecting physician work RVU increase and imaging guidance reimbursement. The European Union’s Medical Device Regulation (EU MDR 2017/745) full enforcement (May 2025) reclassifies PICCs as Class III devices (highest risk, due to direct contact with central circulation and potential for fatal air embolism). Notified body conformity assessment requires clinical evaluation report (CER) with literature review (n≥20 published studies) and post-market clinical follow-up (PMCF) plan. Compliance cost per device family: EUR 75,000-150,000, with annual surveillance fees. China’s National Medical Products Administration (NMPA) updated “Guidelines for PICC Registration” (March 2025), requiring animal studies (porcine model, n≥6) for thrombogenicity (7-day implantation, histopathology grade ≤2 of 4), antimicrobial coating efficacy (ISO 22196 modified), and 12-month real-time aging for sterile packaging.
4. Competitive Landscape & Regional Market Share Dynamics
The Peripherally Inserted Central Catheter (PICC Line) market is segmented as below:
Key players:
BD (Becton, Dickinson and Company – US, PowerPICC, Maximal Barrier Trays), Cardinal Health (US – Kendall PICC, Kinney brand), AngioDynamics (US – BioFlo, NanoKnife platform), Teleflex (US – Arrow PICC line, Groshong valve), B. Braun (Germany – Certofix PICC, Introcan), Vygon (France – LeaderCath, Piccolo pediatric), Spectrum Vascular (US – Spectra PICC), Argon Medical (US – CleanGuard PICC), Medcomp (US – Pedi-PICC, power-injectable), Health Line (China), Branden (China), Foshan Special Medical (China), Zhengzhou DIALL Medical Technology (China), Shandong Ande Healthcare Apparatus (China)
Segment by Product Type:
- Valve-type PICC – 55-60% of market share by value, 40-45% by volume
- Open-end PICC – 40-45% of market share by value, 55-60% by volume
Segment by Patient Population:
- Adult – 85-90% of PICC placements (chemotherapy, TPN, long-term antibiotics)
- Pediatric (including neonatal) – 10-15% of placements (specialized small-bore catheters)
Regional market share estimates 2025 (value):
- North America: 42% (US 38%, Canada 4%) – Highest valve-type and antimicrobial-coated penetration
- Europe: 28% (Germany 7%, France 5%, UK 5%, Italy 3%, others 8%) – Strong home infusion programs
- Asia-Pacific: 22% (China 10%, Japan 5%, India 4%, South Korea 2%, others 1%) – Fastest-growing, open-end dominant
- Rest of World: 8% (Latin America, Middle East, Africa)
Exclusive insight (原创观察): A critical and underreported dynamic is the divergence between integrated PICC placement programs (hospital-based vascular access teams, PICC nurses with ultrasound training) and ad hoc PICC placement (interventional radiology, anesthesiology, or surgery placing PICCs as part of broader practice). Hospitals with dedicated PICC teams (typically 2-5 full-time vascular access nurses) achieve lower CLABSI rates (0.5-1.0 per 1,000 line-days vs. 2.0-3.0 for ad hoc placement), higher first-attempt success rates (95% vs. 80-85%), and lower insertion costs (US200−300vs.US200−300vs.US 400-600 due to reduced imaging and consult fees). By 2028, we project dedicated PICC teams will be standard in >80% of US hospitals >200 beds (up from 60% in 2025), driving market share toward premium catheters (valve-type, antimicrobial coatings) favored by specialized teams, while open-end PICCs will remain dominant in smaller hospitals, emerging markets, and pediatric settings where dedicated teams are less common.
5. Technical Hurdles and Future Research Directions
Despite widespread adoption, clinical challenges remain:
- Catheter-related thrombosis (CRT): Symptomatic CRT occurs in 5-15% of PICC placements (asymptomatic 30-50%), causing arm swelling, pain, and pulmonary embolism (rare). Risk factors: larger catheter-to-vein ratio (CRT risk increases 3x for >45% occlusion), cancer (hypercoagulable state), and catheter tip position (non-SVC placement higher risk). Mitigation includes small French size (4 Fr vs. 5 Fr), routine flushing, and anticoagulation for high-risk patients (prophylactic rivaroxaban or apixaban in cancer patients, off-label).
- CLABSI despite antimicrobial coatings: Coated PICCs reduce but do not eliminate CLABSI (absolute risk reduction 2-4% from baseline 5-8% in high-risk patients). Biofilm formation on internal lumen (despite external coating) and port contamination (during access) remain failure modes. Next-generation coatings (nitric oxide-releasing, biofilm-disrupting enzymes) are in development but not yet commercially available.
- PICC malposition and tip migration: Tip positioned outside SVC (e.g., right atrium, azygos vein, internal jugular vein) occurs in 3-7% of insertions despite ECG or fluoroscopy guidance. Migration over time (tip advances or retracts with arm movement, respiration) occurs in 5-10% of patients with dwell times >3 months, requiring repeat imaging and potential repositioning or replacement.
Future Market Research priorities should address:
- Biofilm-resistant internal lumen coatings – Developing polymer coatings that prevent bacterial adhesion and biofilm formation on inner catheter surface (current antimicrobial coatings are external only, leaving lumen vulnerable)
- Smart PICCs with embedded sensors – Fiberoptic sensors for continuous central venous pressure monitoring, pH, or temperature; prototype devices exist but lack sterilization validation and regulatory approval
- Self-flushing valve designs – Eliminating need for routine flush schedules (weekly for valve-type, daily for open-end) through slow-release osmotic systems or fluidics-driven passive flushing; target 30-day maintenance-free operation
- Pediatric-specific valve-type PICCs – Silicone 2-3 Fr catheters with pressure-activated valves (currently, smallest valve-type PICC is 3.5 Fr BD PowerPICC, still large for neonates <2 kg)
- Artificial intelligence for tip position confirmation – Machine learning models analyzing ECG waveforms (intracavitary ECG method) to automatically confirm tip position in SVC vs. right atrium, reducing chest X-ray utilization (current standard, but exposes patient to radiation and adds US$ 50-100 cost)
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666 (US)
JP: https://www.qyresearch.co.jp
